Data Foundry

Drug recalls 2023

Sensorcaine-MPF — Class II drug recall D-0129-2023

Terminated recall by Fresenius Kabi USA, LLC, reported 2023-01-25, distributed nationwide. Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Recall numberD-0129-2023
Product typeDrug
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmFresenius Kabi USA, LLC, Lake Zurich, IL, United States
Recall initiated2022-11-22
Classified2023-01-13
Reported by FDA2023-01-25
Terminated2023-10-23
DistributedNationwide (US)
Quantity31,600 vials
Reason classespotency
NDC63323-0461, 63323-0461-01, 63323-0461-57, 63323-0463, 63323-0463-01, 63323-0463-57, 63323-0468, 63323-0468-01, 63323-0468-02, 63323-0468-17, 63323-0468-37, 63323-0472, 63323-0472-01, 63323-0472-03, 63323-0472-17, 63323-0472-37
Lot numbers6128800
Expiration dates2023-12

Product

Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.25%, 25 mg per 10 mL (2.5 mg per mL), 10 mL Single Dose Vial (NDC 63323-468-01), packaged in 25 Single Dose Vials per tray (NDC 63323-468-17), Rx only, Fresenius Kabi, Lake Zurich, IL 60047.

Reason for recall

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0129-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.